As of 2026-03-29, the Relative Valuation of Kezar Life Sciences Inc (KZR) is (207.68) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.20 USD, the upside of Kezar Life Sciences Inc based on Relative Valuation is -3449.7%.
The range of the Relative Valuation is (193.42) - (211.79) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.6x - 24.4x | 22.0x |
| Forward P/E multiples | 20.0x - 21.9x | 21.0x |
| Fair Price | (193.42) - (211.79) | (207.68) |
| Upside | -3219.6% - -3516.0% | -3449.7% |
| Date | P/E |
| 2026-03-19 | -0.69 |
| 2026-03-18 | -0.70 |
| 2026-03-17 | -0.70 |
| 2026-03-16 | -0.71 |
| 2026-03-13 | -0.71 |
| 2026-03-12 | -0.74 |
| 2026-03-11 | -0.73 |
| 2026-03-10 | -0.74 |
| 2026-03-09 | -0.72 |
| 2026-03-06 | -0.72 |
| 2026-03-05 | -0.71 |
| 2026-03-04 | -0.76 |
| 2026-03-03 | -0.73 |
| 2026-03-02 | -0.73 |
| 2026-02-27 | -0.69 |
| 2026-02-26 | -0.69 |
| 2026-02-25 | -0.70 |
| 2026-02-24 | -0.70 |
| 2026-02-23 | -0.70 |
| 2026-02-20 | -0.71 |
| 2026-02-19 | -0.69 |
| 2026-02-18 | -0.68 |
| 2026-02-17 | -0.65 |
| 2026-02-13 | -0.65 |
| 2026-02-12 | -0.65 |
| 2026-02-11 | -0.66 |
| 2026-02-10 | -0.64 |
| 2026-02-09 | -0.64 |
| 2026-02-06 | -0.63 |
| 2026-02-05 | -0.62 |
| 2026-02-04 | -0.63 |
| 2026-02-03 | -0.63 |
| 2026-02-02 | -0.63 |
| 2026-01-30 | -0.63 |
| 2026-01-29 | -0.64 |
| 2026-01-28 | -0.64 |
| 2026-01-27 | -0.64 |
| 2026-01-26 | -0.64 |
| 2026-01-23 | -0.64 |
| 2026-01-22 | -0.64 |
| 2026-01-21 | -0.64 |
| 2026-01-20 | -0.64 |
| 2026-01-16 | -0.64 |
| 2026-01-15 | -0.64 |
| 2026-01-14 | -0.64 |
| 2026-01-13 | -0.64 |
| 2026-01-12 | -0.63 |
| 2026-01-09 | -0.64 |
| 2026-01-08 | -0.67 |
| 2026-01-07 | -0.65 |